RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

 
  • Regulatory NewsRegulatory News

    Former Insys Executives Arrested on Racketeering Charges

    Six former Insys Therapeutics executives and managers were arrested on Thursday on charges that they conspired to bribe healthcare practitioners to prescribe the company's fast-acting fentanyl spray Subsys. Background The US Food and Drug Administration (FDA) approved Subsys in 2012 with a narrow indication for managing "breakthrough pain in adult cancer patients who are already receiving and who are tolerant to around-the-clock opioid therapy for underlying persisten...
  • Regulatory NewsRegulatory News

    MHRA Halts Kickback Scheme for Independent Pharmacies

    The UK’s Medicines & Healthcare Products Regulatory Agency on Tuesday said that it shut down a scheme whereby independent pharmacists would accumulate personal spending money based on the sales of certain medicines. The regulator said the Bloc Group Limited’s proposed promotional scheme for healthcare professionals was brought to the attention of MHRA. “Independent pharmacies were offered points on the purchase of medicines. These points accumulated on a card and were ...
  • Novartis Hammered by US Attorneys for Second Time in Four Days as Further Allegations Emerge

    The US subsidiary of pharmaceutical manufacturing giant Novartis has been hit with a lawsuit filed by the federal government, the second in just four days as US attorneys hone in on the company for a string of alleged infractions that now include paying kickbacks to individuals and companies in return for prescribing the company's medication in place of others'. Background Novartis' week was already off to a bad start, having been accused by the US government of condu...
  • Big Pharma Faces Prospect of Big Fines in 2012

    • 23 January 2012
    Some of the world's largest pharmaceutical companies are facing "costly settlements" during 2012 thanks to aggressive investigations and enforcement by US agencies and a wide-ranging list of improper activities allegedly perpetrated by the pharmaceutical companies, according to an analysis by The Financial Times . US agencies are currently separately investigating Pfizer, GlaxoSmithKline, Merck, Baxter, Bristol Myers Squibb, Eli Lilly, AstraZeneca and Smith & Neph...